Novavax reported the beginning of a Part II trial for its COVID-19-Influenza Mixture (CIC) and influenza stand-alone vaccine candidates. The dose-confirming trial will consider the security and immunogenicity of various formulations of the CIC and influenza vaccine candidates in adults aged 50 by means of 80.
“We’re inspired by the initiation of this trial given the optimistic outcomes shared earlier this yr from our Part I/II trial, the primary of its variety to judge a mixed COVID-19 and influenza vaccine,” stated Stanley C. Erck, president and CEO, Novavax. “We consider that like influenza, COVID-19 may even be seasonal shifting ahead, and that there’s room out there for brand spanking new alternate options to offer higher safety towards the affect of influenza, significantly in older adults, and to discover the potential to mix this with safety from COVID.”
The randomized, observer-blinded trial will assess a mix of Novavax’s recombinant protein-based COVID-19 vaccine (NVX-CoV2373), quadrivalent influenza vaccine candidate, and patented saponin-based Matrix-M adjuvant. Major and secondary targets of the research are to evaluate the security, tolerability, and immune responses to varied formulations of the CIC and influenza vaccine candidates. The Part II dose-confirmation trial shall be performed in two components and seeks to enroll a complete of roughly 2,300 members throughout a number of websites situated in Australia and New Zealand.
Preliminary outcomes of the trial are anticipated mid-year 2023.
